BACKGROUND
Everolimus-based endocrine therapy is used for estrogen receptor-positive/human epidermal growth factor receptor 2-negative (ER-positive/HER2-negative) metastatic breast cancer after cyclin-dependent kinase 4/6 (CDK4/6) inhibitor treatment, but factors associated with treatment durability remain unclear. We...
Hikari Kiyohara, Toru Hanamura, Y. Sagara et al.· Breast Cancer· 0 citations
Background/Aim: Germline BRCA1/2 mutations (gBRCA1/2m) confer a markedly increased lifetime risk of breast cancer. Although diverse second-hit mechanisms lead to biallelic inactivation of BRCA1/2, their relationship with the immune microenvironment remains poorly understood, particularly in Japanese populations. Patien...
Yukino Kawamura, K. Mori, F. Takeuchi et al.· Anticancer Research· 0 citations
BACKGROUND
The randomised phase III OlympiA trial (NCT02032823) compared 1 year of adjuvant olaparib (oral poly-(ADP-ribose) polymerase [PARP] inhibitor) to placebo in 1,836 patients with pathogenic/likely pathogenic BRCA1 or BRCA2 (gBRCApv) germline variants and high-risk human epidermal growth factor receptor 2 (HER2...
J. Garber, D. Cameron, C. Campbell et al.· Annals of Oncology· 1 citation
Current evidence and ongoing studies on treatment de-escalation across breast cancer subtypes are summarized and integration of molecular biomarkers with response-adapted strategies may further refine risk stratification and support personalized treatment approaches.
M. Ono, Y. Sagara, Toshiyuki Ishiba et al.· Japanese Journal of Clinical...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.